A 22-year-old man, in first complete remission of acute myelogenous leukemia, developed a high grade B cell lymphoma 19 months after an allogeneic bone marrow transplant (allo-BMT) from an HLA-identical unrelated donor. Biopsy of a cervical lymph node revealed a lymphoma that was negative for Epstein-Barr virusencoded small nuclear RNAs (EBERs) in situ hybridization. Genotypic analyses identified the lymphoma to be of donor origin, and there was no evidence of the Epstein-Barr virus (EBV) DNA in the lymphoma by Southern blot analysis. The lymphoma went into complete remission, following four courses of combination chemotherapy, but relapsed after a month and the patient died of congestive heart failure. The patient was thought to be persistently immunosuppressed 11 months after cessation of immunosuppressants, and the lymphoma was thought to be induced by one or more factors other than EBV. Bone Marrow Transplantation (2000) 26, 577-579.
Allogeneic bone marrow transplantation (allo-BMT) is a curative treatment for many patients with hematological malignancies. With the improvement in survival, recipients of BMT have a significant risk of developing secondary malignancies, including non-Hodgkin's lymphoma. 1 Two types of lymphoproliferative disorders have been reported after allo-BMT; the most frequent is a B cell lymphoproliferative disorder arising in the first year following BMT. It is almost always associated with Epstein-Barr virus (EBV) infection, often pursues a fatal course, and is of donor origin. [1] [2] [3] [4] [5] [6] The other is a late-onset malignant lymphoma, which develops more than 1 year after BMT. It is either of donor or recipient origin and is histologically heterogeneous. [7] [8] [9] [10] We report a case of high grade B cell lymphoma of donor origin, which did not contain the EBV genome, diagnosed 19 months following allo-BMT.
Case report
A 22-year-old man developed abdominal pain and appetite loss in early September 1998. He had undergone BMT from an HLA-identical unrelated donor in January 1997 when he was in first complete remission (CR) of acute myelogenous leukemia (AML). Prior to BMT, he had received DCMP induction chemotherapy (daunorubicin 40 mg/m 2 daily for 5 days, cytarabine 80 mg/m 2 daily for 10 days, 6-mercaptopurine 70 mg/m 2 daily for 10 days, prednisolone 40 mg/m 2 daily for 4 days), three courses of consolidation therapy and two courses of maintenance therapy including daunorubicin and mitoxantrone. Pretransplant, conditioning consisted of cyclophosphamide (60 mg/kg × 2 doses), cytarabine (2.0 g/m 2 × 4 doses), and total body irradiation (12 Gy in four fractions). Tacrolimus hydrate and a short course of methotrexate were administered for graft-versus-host disease (GVHD) prophylaxis. Immunosuppressive therapy was discontinued 8 months post transplant. No severe infectious complication or chronic GVHD occurred during the post-BMT period. Bone marrow aspiration in July 1998 revealed CR. On admission, he had right lateroabdominal pain, appetite loss and systemic lymphadenopathy. Biochemical examination showed an increase of LDH (4000 IU/l) and soluble IL-2 receptor (12 000 IU/l). CT scans demonstrated cervical, axillar, mediastinal and abdominal lymphadenopathy. Cervical lymph node biopsy revealed small non-cleaved B cell lymphoma (Figure 1 ). In these lymphoma cells, monoclonal rearrangement of the immunoglobulin heavy chain gene was detected. In situ hybridization for EBV-encoded small nuclear RNAs (EBERs) was negative and EBV DNA by Southern blot analysis was also negative. DNA analysis of mononuclear cells in peripheral blood, oral mucosa and lymphoma cells, revealed that the lymphoma cells were derived from donor cells (Figure 2 ). Bone marrow aspiration showed 3.8% myeloperoxidase-negative lymphoma cells and no evidence of AML relapse. The patient was treated with four courses of combination chemotherapy (alternating cycles of CODOX-M: cyclophosphamide, vincristine, doxorubicin, methotrexate and IVAC: ifosphamide, etoposide, cytarabine). 11 This treatment resulted in complete resolution of the tumors. A month later, the patient was readmitted with general fatigue and cervical lymphadenopathy. He had a leukocytosis (54 400/l) and almost all of these leukocytes were lymphoma cells. He was treated with combination chemotherapy (doxorubicin, vincristine, cyclophosphamide, prenisolone, l-asparaginase). The lymphoma cells disappeared, but in May 1999 he died of congestive heart failure probably due to drug-induced cardiomyopathy, since he had received in total doxorubicin 320 mg/m 2 , mitoxantrone 30 mg/m 2 and daunorubicin 530 mg/m 2 .
Discussion
Post-BMT neoplasms are emerging as one of the serious complications in survivors of BMT. Bhatia et al 1 reported that among 2150 patients who underwent BMT, 53 had post-BMT malignancies, which represents an 11-fold increased risk over that of comparable normal populations. Non-Hodgkin's lymphoma, including post-transplant lymphoproliferative disorders (PTLPD), is the most common secondary malignancy following BMT. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Two types of malignant lymphomas have been reported after allo-BMT. 4, 9 Most lymphomas are PTLPD and arise in the first year following BMT. These are almost always associated with EBV infection and are usually of donor origin. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] PTLPD in bone marrow transplant recipients appear to have a similar aggressive course and poor outcome. Overall, there was a fatal outcome in 90% of cases.
2 Risk of PTLPD was associated with receiving an HLA-mismatched transplant, receiving T cell-depleted marrow, use of ATG in the preparative regimen or as a GVHD prophylaxis, use of busulphan in the preparative regimen, and immunosuppressive therapy. All of these procedures tend to compromise host immunity.
1,2 On the other hand, lymphoma occurring more than 1 year after BMT (19 months in our case) is very heterogeneous. These lymphomas are either of donor or of recipient origin. Many late-onset post-transplant lymphomas of donor origin are associated with EBV, but in lymphomas of recipient origin, many cases have not associated with EBV. In these cases, chemotherapy and/or radiation before BMT might effect secondary carcinogenesis. However, there are few reports of PTLPD in which lymphoma cell origin and presence of EBV infection were completely ascertained.
In our case, the lymphoma was of the late-onset type, and DNA analysis of lymphoma cells, oral mucosa and peripheral blood mononuclear cells revealed that it was of donor origin. Both in situ hybridization and Southern blot analysis revealed the absence of EBV in the lymphoma cells. In many cases of post transplant, late-onset lymphoma of donor origin, immunosuppression after BMT is thought to be one of the causes of the secondary malignancy. 9 In our case, the patient had no GVHD, and tacrolimus had been stopped 11 months before lymphoma onset. However, we assume that he must have been immunocompromised at the time of lymphoma onset because of being post UR-BMT.
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